INTERPACE BIOSCIENCES, INC. (IDXG) Total liabilities 2016–2025
INTERPACE BIOSCIENCES, INC. (IDXG) total liabilities at each fiscal year-end, per SEC filings.
$11.5MFY2025 · since FY2016: $35.2M → $11.5M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $11.5M | -32.5% |
| FY2024 | $17.0M | -23.1% |
| FY2023 | $22.1M | -32.0% |
| FY2022 | $32.5M | -5.2% |
| FY2021 | $34.3M | +21.5% |
| FY2020 | $28.2M | -5.4% |
| FY2019 | $29.8M | +90.3% |
| FY2018 | $15.7M | +14.2% |
| FY2017 | $13.7M | -61.0% |
| FY2016 | $35.2M | — |
Years the filer does not tag total liabilities directly are shown as reported total assets − reported shareholders’ equity at the same fiscal year-end.
Source: SEC XBRL filings · For reference only · Not investment advice
More IDXG financial trends
IDXG RevenueIDXG Net incomeIDXG Net marginIDXG Gross profitIDXG Gross marginIDXG Operating incomeIDXG Operating marginIDXG Operating cash flowIDXG Free cash flowIDXG Capital expendituresIDXG Return on equityIDXG Stock buybacksIDXG Dividends paidIDXG Total assetsIDXG Shareholders’ equityIDXG overview →